WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) began its rolling U.S. application for QTORIN rapamycin during the second quarter as higher clinical, manufacturing and regulatory spending more than doubled the biotechnology company’s net loss to $21.9 million.
Palvella submitted the first module of its New Drug Application to the U.S. Food and Drug Administration seeking approval of QTORIN rapamycin for microcystic lymphatic malformations, or microcystic LMs. The company expects to complete the application in the second half of 2026 and is preparing for a standalone U.S. commercial launch in the first half of 2027 if approved.
The FDA granted Rolling Review following an in-person pre-NDA meeting covering nonclinical, clinical pharmacology, clinical information and the planned evidence package. The designation allows the agency to review completed portions of the application before receiving the full submission.
QTORIN rapamycin has also received Breakthrough Therapy and Fast Track designations for microcystic LMs, a condition for which Palvella reports there are currently no FDA-approved therapies.
“We are working closely with FDA under the program’s Breakthrough Therapy and Fast Track designations to expedite development and review,” founder and Chief Executive Officer Wes Kaupinen stated.
The regulatory push follows Palvella’s Phase 3 SELVA trial. Additional data presented by James Treat of Children’s Hospital of Philadelphia showed a statistically significant improvement among patients ages 6 to 11, along with other findings involving clinical signs and patient-reported outcomes, according to the company.
Palvella is simultaneously expanding development of its QTORIN platform into other rare skin diseases and vascular malformations.
For cutaneous venous malformations, the company plans to begin a Phase 3 trial in the fourth quarter following an End-of-Phase 2 meeting. Phase 2 TOIVA data presented this year showed all patients who had bleeding at baseline improved on an investigator assessment of bleeding at Week 12, according to Palvella.
Additional 24-week TOIVA results showed statistically significant improvements in measures of lesion height or engorgement and appearance at each measured time point, with clinical response increasing with longer treatment duration.
Palvella has also begun dosing patients in LOTU, a multicenter Phase 2 study of QTORIN rapamycin for clinically significant angiokeratomas. The company expects topline results in the second half of 2027.
Another candidate, QTORIN pitavastatin, is expected to enter a Phase 2 trial for disseminated superficial actinic porokeratosis in the second half of 2026.
Palvella recently strengthened the intellectual property covering that program through U.S. Patent No. 12,636,273, which is exclusively licensed from Yale University. The patent covers topical administration of HMG-CoA reductase inhibitors, including pitavastatin, for porokeratosis and provides protection into 2043.
The company plans to identify a fourth target indication for QTORIN rapamycin and a third QTORIN platform product candidate during the second half of 2026.
Those development and commercialization preparations are increasing Palvella’s spending. Research and development expenses rose to $12.5 million in the second quarter from $5.1 million a year earlier.
The increase reflected manufacturing expenses, development of QTORIN rapamycin for angiokeratomas, costs associated with the rolling NDA and higher personnel and consulting expenses.
General and administrative expenses increased to $8.9 million from $4.1 million, driven primarily by additional personnel and professional services associated with operating as a publicly traded company.
Palvella consequently recorded a second-quarter net loss of $21.9 million, or $1.52 per share, compared with a loss of $9.5 million, or 86 cents per share, a year earlier.
The company had $250.6 million in cash, cash equivalents and short-term investments as of June 30.
Palvella also recently moved its shares to the Nasdaq Global Market and appointed biotechnology executive Matt Pauls to its board of directors. Pauls has held executive or board positions at Savara Inc., Soleno Therapeutics, Strongbridge Biopharma and Insmed Incorporated.
As of July 31, Palvella reported 15.8 million shares outstanding, including 14.4 million common shares and about 1.4 million common-share equivalents assuming conversion of outstanding pre-funded warrants.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.